Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Cagrilintide

AM-833, Long-acting amylin analogue

Quick Stats
Studies 57
Trials 38
Recruiting PHASE3 INTERVENTIONAL NCT07220642

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment participants get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. Possible side effects will be followed carefully during the study. For each participant, the study will last for about 1 year and 6 months.

Interventions

Name: Cagrilintide
Type: DRUG
Description: Cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.
Name: Placebo
Type: DRUG
Description: Placebo matched to cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.

Primary Outcomes

Measure: Relative change in body weight
TimeFrame: From baseline (week 0) to end of treatment (week 64)
Description: Measured as percentage (%) of body weight.
Measure: Number of participants with achievement of greater than or equals (>=) 5 percent (%) body weight reduction
TimeFrame: From baseline (week 0) to end of treatment (week 64)
Description: Measured as count of participants.

Trial Information

NCT ID

NCT07220642

Status

Recruiting

Study Type

INTERVENTIONAL

Phases

PHASE3

Sponsor

Novo Nordisk A/S

Last Updated

December 15, 2025